Filed April 24, 2018

Serial No. 79237055

Registered April 14, 2020

Registration No. 6,031,354

Class Pharmaceutical and medical preparations and substances in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols, for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical and medical preparations with cannabinoids as active ingredient, namely, a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; pharmaceutical preparations and substances for the treatment of epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical preparations and substances for the treatment of convulsions and seizures associated with epilepsy associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; pharmaceutical and medical preparations for the treatment of symptoms associated with epilepsy including pain, muscle spasticity and spasms, bladder problems and sleep disorders associated with Dravet Syndrome and Lennox-Gestaut Syndrome in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols; medicinal oils in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of Dravet Syndrome and Lennox-Gestaut Syndrome; medicinal infusions in the nature of a drug product in finished dosage formulation that contains cannabidiol derived from cannabis and no more than 0.1 percent residual tetrahydrocannabinols for the treatment of epilepsy, convulsions and seizures associated with Dravet Syndrome and Lennox-Gestaut Syndrome; 006; 018; 044; 046; 051; 052

Case Type Trademark